Mohammadzadeh, Zahra and Khaksari, Mohammad and Nematollahi, Mohammad Hadi and Kheirandish, Reza and Moslemizadeh, Amirhossein and Delshad, Sina and Faramarz, Sanaz and Tezerji, Sara Sheibani and Torkashvand, Mohammad and Shahba, Samira and Bashiri, Hamideh (2025) Therapeutic efficacy to dose-dependent toxicity of Cabazitaxel in C6-induced glioblastoma model of rats. TOXICOLOGY RESEARCH, 14 (2): tfaf048. ISSN 2045-452X, 2045-4538
Full text not available from this repository. (Request a copy)Abstract
This study was designed to adjust effective chemotherapy doses of cabazitaxel (CBZ) on cognitive behaviors, inflammatory cytokines and oxidative stress parameters, and survival rate in C6-induced GBM of rats. Male Sprague-Dawley rats bearing intra-caudate nucleus (CN) C6 inoculation were randomly divided into nine groups as follows: sham, tumor, Temozolomide (TMZ) vehicle, TMZ, CBZ vehicle, CBZ at doses of 0.5, 1, 2 and 4 mg/kg. Behavioral tests survival rate, histopathology, immunohistochemistry, oxidative stress, and inflammatory cytokines were evaluated. All drug treatments reduced the volume and number of tumor cells dose-dependently and CBZ4 was able to cause the greatest reduction. The %Survival rate of animals using CBZ1 significantly increased compared to other treatment groups. CBZ1 reduced anxiety-like behaviors and increased the balance of the animal with GBM. CBZ1 and CBZ2 groups improved C6-induced learning disabilities. Treatments could ameliorate tumor-induced dysregulation of oxidative stress. TNF-alpha/IL-10 decreased in the CBZ1 group compared to other treatment groups, which may indicate an improvement in inflammatory balance. Our findings demonstrate that the administration of CBZ at a dosage of 1 mg/kg exerts advantageous impacts on both the survival rate and neurocognitive performance of rats within the GBM model. However, our results showed that CBZ may have toxic effects, especially in a dose of 4 mg/kg.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TOTAL ANTIOXIDANT CAPACITY; RESISTANT PROSTATE-CANCER; DNA-DAMAGE; GLIOMA; TEMOZOLOMIDE; DOCETAXEL; ADULT; ALPHA; glioblastoma; Temozolomide (TMZ); Cabazitaxel (CBZ); cognitive behavior; inflammatory factors; oxidative stress |
| Subjects: | 500 Science > 570 Life sciences 500 Science > 590 Zoological sciences |
| Divisions: | Biology, Preclinical Medicine > Institut für Zoologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Apr 2026 09:47 |
| Last Modified: | 23 Apr 2026 09:47 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67594 |
Actions (login required)
 |
View Item |
